Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00034593 | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 3 | Jul 19, 2006 | clinicaltrials |
| NCT00035061 | A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00343356 | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | completed | Phase 2 | 138 | LanZhou UniversityOTHER | 0 | Jun 22, 2006 | clinicaltrials |
Data updated 23 days agoSource updated May 17, 2007source: clinicaltrials